News and Stories

November 30, 2023

Everything You Need to Know About HIV Testing

Whether you are sexually active or just want to stay informed, being aware of your HIV status is an important step in taking charge of your sexual health. 

Read More
November 10, 2023

Unveiling the World of Genetic Counseling: An Interview with Elizabeth Melchionna

In honor of Genetic Counselor Awareness Day, we had the privilege of speaking with Elizabeth Melchionna, a genetic counselor at HNL Lab Medicine. 

Read More
November 06, 2023

Gut Check: Clostridium difficile

Clostridioides difficile, commonly known as C. diff, is a bacterium that can cause infections in the colon, leading to a range of symptoms that can be uncomfortable and, in some cases, serious.

Read More
November 03, 2023

Celebrating Our Commitment to Quality: Recent CAP Inspection Validates HNL Lab Medicine’s Excellence

At HNL Lab Medicine, we are thrilled to share a significant milestone that exemplifies our commitment to delivering exceptional quality healthcare.

Read More
October 29, 2023

World Stroke Day

Sharing a Personal Experience on World Stroke Day to Raise Awareness about Strokes.

Read More
News and Stories

October 28, 2022

B-cell lymphoma is a large group of heterogenous disorders and comprises a majority of non-Hodgkin lymphomas. As a poor survival rate characterizes these aggressive lymphomas, early detection and treatment is vital. Fluorescence in situ hybridization (FISH) is a sensitive method to detect smaller genomic changes associated with various hematological malignancies and solid tumors. The high sensitivity of FISH analysis detects low-level clones and identifies prognostically and therapeutically important genetic abnormalities. This new in-house panel delivers prompt results and complements HNL Genomics offerings.


The non-Hodgkin lymphoma FISH panel detects IGH gene translocations or rearrangements involving the 14q32 locus. Included in this group are follicular lymphoma (FL), Burkitt Lymphoma (BL), and diffuse large B-cell lymphoma (DLBCL). The characteristic chromosome abnormality t(14;18) resulting in IGH/BCL2 fusion is seen in about 80% of FL and about 20-30% of DLBCL. A majority of patients with BL harbor the characteristic t(8;14), resulting in c-MYC/IGH fusion. BCL6 gene rearrangements are also associated with B-cell lymphoma. Cyclin D1 gene rearrangements, especially the t(11;14), distinguish mantle cell lymphoma (ML) from other lymphoproliferative disorders, hence are diagnostic for ML.


There are several advantages of FISH technology over routine chromosome analysis, including the ability of FISH technology to detect genomic abnormalities in non-viable and non-dividing tissues, rapid turnaround time, and increased resolution. However, FISH technology is complementary to routine chromosome analysis and cannot substitute routine chromosome analysis for the diagnosis of cancer.
Providers suspecting non-Hodgkin lymphoma can order this panel easily using the test code FPNHL. Our genetic testing experts are available to assist with any questions. The average turnaround time for our non-Hodgkin lymphoma FISH panel is 3-4 days. Results are available in EPIC.

Test Summary

  • Non-Hodgkin lymphoma FISH panel
  • Detects most common abnormalities related to Non-Hodgkins Lymphoma (NHL) by chromosome analysis and FISH testing.
  • Test Code FPNHL
  • Turnaround time: 3-4 days

Time matters to your patients. HNL Lab Medicine delivers patient results quickly and conveniently. Please take advantage of our newly available non-Hodgkin lymphoma FISH panel to provide superior patient care.

For questions or assistance, please call 877-402-4221. For technical questions related to this test, please ask for Technical Support between the hours of 8 a.m. to 4:30 p.m. For general inquiries, Customer Care is available to assist at any time.

Following are the probes included in the NHL panel.